SCHEMBL22944867

SCHEMBL22944867

CCCn1nc[nH]c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1723957 0.88 ADORA2A (0.43)
SCHEMBL5486374 0.86 ADORA2B (0.42)
SCHEMBL2826206 0.85 ADORA2B (0.44)
SCHEMBL176271 0.83
SCHEMBL31330327 0.82 ADORA2A (0.33)
SCHEMBL31330313 0.78 ADORA2A (0.33)
SCHEMBL31330241 0.78 ADORA2A (0.33)
SCHEMBL31330324 0.76 ADORA2A (0.33)
SCHEMBL11402130 0.72 GRIA1 (0.49)
SCHEMBL31330320 0.72 ADORA3 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024249959-A1 COMPOSITIONS REDUCING THE EXPRESSION OR ACTIVITY OF C1 GALT1 FOR TREATING EWING SARCOMA UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) 2024-12-05 WO disclosed
WO-2021021761-A1 UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION NURIX THERAPEUTICS, INC. (US) 2021-02-04 WO disclosed